Literature DB >> 20953850

Fevers and the rheumatologist.

Prudence Joan Manners1, Robin Guttinger.   

Abstract

Fevers in children are mainly due to infection, malignancy or inflammatory conditions. Rheumatologists have an important role in the care of inflammatory conditions, many of which are associated with fevers. Seven conditions, the hereditary recurrent fever syndromes, have been defined with the presenting symptom of recurring fever, and for which mutation of a single gene has been defined: Chronic infantile neurological articular syndrome (CINCA), Familial cold autoinflammatory syndrome (FACS), Familial Mediterranean fever (FMF), hyperimmunoglobulinemia D (HIDS), Muckle-Wells syndrome (MWS), Pyogenic sterile arthritis and Pyoderma gangrenosum (PAPA) and Tumour necrosis factor receptor-associated periodic syndrome (TRAPS) . These conditions will be discussed in detail in regard to how they fit into the wider picture of pediatric rheumatological conditions, how the diagnoses may be established and the current recommended treatments for each condition.

Entities:  

Mesh:

Year:  2010        PMID: 20953850     DOI: 10.1007/s12098-010-0206-y

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  29 in total

1.  Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever.

Authors:  F Marchetti; E Barbi; A Tommasini; C Oretti; A Ventura
Journal:  Clin Exp Rheumatol       Date:  2004 Nov-Dec       Impact factor: 4.473

Review 2.  Is there a role for the otolaryngologist in PFAPA syndrome? A systematic review.

Authors:  S C L Leong; P D Karkos; M T Apostolidou
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2006-08-14       Impact factor: 1.675

Review 3.  Familial Mediterranean fever.

Authors:  Aysin Bakkaloglu
Journal:  Pediatr Nephrol       Date:  2003-06-27       Impact factor: 3.714

Review 4.  Autoinflammatory diseases: clinical and genetic advances.

Authors:  Sharifeh Farasat; Ivona Aksentijevich; Jorge R Toro
Journal:  Arch Dermatol       Date:  2008-03

5.  Use of canakinumab in the cryopyrin-associated periodic syndrome.

Authors:  Helen J Lachmann; Isabelle Kone-Paut; Jasmin B Kuemmerle-Deschner; Kieron S Leslie; Eric Hachulla; Pierre Quartier; Xavier Gitton; Albert Widmer; Neha Patel; Philip N Hawkins
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

6.  Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome.

Authors:  Jeroen C H van der Hilst; Evelien J Bodar; Karyl S Barron; Joost Frenkel; Joost P H Drenth; Jos W M van der Meer; Anna Simon
Journal:  Medicine (Baltimore)       Date:  2008-11       Impact factor: 1.889

7.  Mevalonate kinase deficiency: enlarging the clinical and biochemical spectrum.

Authors:  Viola Prietsch; Ertan Mayatepek; Hermann Krastel; Dorothea Haas; Dorothee Zundel; Hans R Waterham; Ronald J A Wanders; K Michael Gibson; Georg F Hoffmann
Journal:  Pediatrics       Date:  2003-02       Impact factor: 7.124

8.  Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome.

Authors:  Kazuki Takada; Ivona Aksentijevich; Vijayabhanu Mahadevan; Jane A Dean; Richard I Kelley; Daniel L Kastner
Journal:  Arthritis Rheum       Date:  2003-09

9.  Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist.

Authors:  Hal M Hoffman; Sanna Rosengren; David L Boyle; Jae Y Cho; Jyothi Nayar; James L Mueller; Justin P Anderson; Alan A Wanderer; Gary S Firestein
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

10.  The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.

Authors:  Lorenzo Calligaris; Federico Marchetti; Alberto Tommasini; Alessandro Ventura
Journal:  Eur J Pediatr       Date:  2007-06-23       Impact factor: 3.183

View more
  1 in total

1.  Fever with Rashes.

Authors:  Letha Soman
Journal:  Indian J Pediatr       Date:  2017-09-23       Impact factor: 5.319

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.